The field is moving away from terms like "castration-resistant" to "androgen pathway modulator resistant" (APMR). This change reflects a broader trend in oncology towards more patient-friendly and medically precise communication, avoiding distressing language.
For biochemically recurrent prostate cancer, the speed at which PSA doubles is a more powerful predictor of outcomes than the absolute value. A doubling time of less than three to nine months indicates highly aggressive disease requiring more intensive treatment consideration.
Patients often assume side effects are unavoidable and don't report them. Nurses should proactively educate patients on available management options to encourage reporting and improve quality of life, as many common toxicities can be effectively mitigated.
Unlike traditional ADT, enzalutamide monotherapy can better preserve sexual activity. However, it leads to compensatory increases in testosterone and estrogen, resulting in gynecomastia, a side effect many men find distressing. This trade-off is a key discussion point.
Loss of the P10 tumor suppressor gene leads to a more aggressive prostate cancer phenotype by activating the PI3K/AKT survival pathway. This genetic alteration also serves as a predictive biomarker for treatment with AKT inhibitors like capivacertib.
The HERO trial demonstrated that the ADT antagonist relugolix has a 54% lower risk of major adverse cardiovascular events compared to the agonist leuprolide. This makes antagonists a safer choice for prostate cancer patients with pre-existing cardiovascular disease.
Unlike other androgen receptor pathway inhibitors (ARPIs), darolutamide does not readily cross the blood-brain barrier. This structural difference leads to a significantly lower incidence of central nervous system side effects, such as cognitive impairment and fatigue.
Some men strongly resist continuous androgen deprivation due to its impact on identity and quality of life. Intermittent therapy, pausing treatment after a good response, offers a compromise, allowing for testosterone recovery and a break from side effects.
Lutetium-PSMA therapy makes patients radioactive for several days, requiring detailed social and logistical planning, such as sleeping separately and avoiding close contact with children. This unique aspect necessitates careful, proactive patient and family education.
A tumor's genetic profile can evolve under treatment pressure. Retesting tissue or blood upon disease progression may reveal new, actionable mutations (e.g., in BRCA genes) that were absent at diagnosis, thereby opening up new targeted therapy options.